Alprostadil
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 354.48 |
Cas No. | 745-65-3 |
Formula | C20H34O5 |
Solubility | insoluble in H2O; ≥13.4 mg/mL in DMSO; ≥47.1 mg/mL in EtOH |
Chemical Name | 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid |
SDF | Download SDF |
Canonical SMILES | CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O |
Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Cell experiment:[1] | |
Cell lines |
Human umbilical vein endothelial cells (HUVECs) |
Reaction Conditions |
0 ~ 10 μM alprostadil |
Applications |
Alprostadil (1 nM ~ 10 μM; 48 h) concentration-dependently reduced HUVEC proliferation (up to 100% inhibition) in the presence of 20 ng/mL vascular endothelial growth factor (VEGF), with an IC50 of 400 nM. Alprostadil (0.01 ~ 10 μM; 6 h) also inhibited VEGF-induced HUVEC migration in a concentration dependent manner, with an IC50 of 500 nM. |
Animal experiment:[1] | |
Animal models |
Female C57/bl6 mice, 6 ~ 8 weeks of age |
Dosage form |
20 ng Administered subcutaneously for 4 days |
Applications |
Alprostadil treatment (20 ng/animal/day; 4 days) significantly inhibited the fibroblast growth factor (FGF)-induced angiogenesis in mice. Alprostadil could be useful for diseases that require anti-angiogenic therapy, such as diabetic retinopathy and solid tumors. |
Note |
The technical data provided above is for reference only. |
References: 1. Cattaneo MG, Pola S, Dehò V, et al. Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay. British Journal of Pharmacology, 2003, 138(2): 377-385. |
Quality Control & MSDS
- View current batch: